Advertisement
Advertisement
DXCM
DexCom, Inc.
62.21
USDSponsored
-0.16
-0.25%
Apr 02, 15:59 UTC -4
Closed
After-Market
61.95
-0.26
-0.42%
DXCM Earnings Reports
Positive Surprise Ratio
DXCM beat 31 of 41 last estimates.
76%
Next Report
Date of Next Report
Apr 23, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.20B
/$0.47
Implied change from Q4 25 (Revenue/ EPS)
-4.86%
/+4.44%
Implied change from Q1 25 (Revenue/ EPS)
+15.67%
/+46.87%
DexCom, Inc. earnings per share and revenue
On Feb 12, 2026, DXCM reported earnings of 0.45 USD per share (EPS) for Q4 25, missing the estimate of 0.66 USD, resulting in a -32.13% surprise. Revenue reached 1.26 billion, compared to an expected 1.27 billion, with a -0.87% difference. The market reacted with a -1.03% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 23 analysts forecast an EPS of 0.47 USD, with revenue projected to reach 1.20 billion USD, implying an increase of 4.44% EPS, and decrease of -4.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
Apr 02, 2026 For Q3 26
Estimate
-$0.11
Actual
$0.02
Surprise
+117.83%
Microbot Medical, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+34.64%
EDAP TMS SA
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.22
Surprise
-69.10%
Xtant Medical Holdings, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.00
Actual
$0.00
Surprise
+100.00%
LENSAR, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.12
Surprise
-68.07%
Atossa Therapeutics, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.16
Actual
-$3.08
Surprise
-165.45%
Adagio Medical Holdings, Inc Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$0.31
Actual
-$0.16
Surprise
+49.40%
American Shared Hospital Services
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.02
Actual
-$0.09
Surprise
-545.54%
PAVmed Inc. Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$5.50
Actual
-$5.52
Surprise
-0.22%
NexGel, Inc Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.12
Surprise
-30.72%
FAQ
What were DexCom, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, DexCom, Inc. reported EPS of $0.45, missing estimates by -32.13%, and revenue of $1.26B, -0.87% below expectations.
How did the market react to DexCom, Inc.'s Q4 2025 earnings?
The stock price moved down -1.03%, changed from $70.98 before the earnings release to $70.25 the day after.
When is DexCom, Inc. expected to report next?
The next earning report is scheduled for Apr 23, 2026.
What are the forecasts for DexCom, Inc.'s next earnings report?
Based on 23
analysts, DexCom, Inc. is expected to report EPS of $0.47 and revenue of $1.20B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement